| EXAGEN INC. DL-,001 |
| USA |
| Gesundheit |
| US30068X1037 / A2PRXT |
| E08A (Frankfurt) / XGN (NASDAQ) |
| FRA:E08A, ETR:E08A, E08A:GR, NASDAQ:XGN |
| - |
| https://exagen.com/ |
|
Exagen Inc. is a commercial-stage diagnostics company focused on autoimmune disease testing. It develops and commercializes blood-based laboratory tests under its AVISE brand, supporting clinicians in the diagnosis, prognosis, and monitoring of compl..
>Volltext.. |
| 185.06 Mio. EUR |
| 187.76 Mio. EUR |
| 63.84 Mio. EUR |
| -9.67 Mio. EUR |
| -16.99 Mio. EUR |
| -0.72 EUR |
| 24.83 Mio. EUR |
| 22.07 Mio. EUR |
| -5.83 Mio. EUR |
| 1.83 |
| 24.63% |
| -14.95% |
| - |
| - |
| - |
| EXAGEN |
| 10.11.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|